Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC518 phase 2a dose-ranging study in Huntington's disease
NL-OMON53484Phase 2Recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of votoplam in Huntington disease (HD), sponsored by PTC Therapeutics, Inc. Primary endpoints: Safety profile and Change in blood total huntingtin protein. Started Nov 2022; status: recruiting.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON53484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53484.